Two formalin-inactivated, decavalent rhinovirus vaccines were tested in humans for acceptability and antigenicity. Infectivity titers of the vaccine antigens were low and ranged from 10(1.5) to 10(5.5) 50% tissue culture infective doses/ml. There were minimal or no side effects to either vaccine. The first inoculation of one vaccine produced antigenic responses to 30% of the administered antigens. Limited testing for heterologous antibody responses to nonvaccine antigens showed scattered responses. These findings suggest that potent multivalent rhinovirus vaccines containing antigens selected for cross-reactivity should be tested in an attempt to develop practical control measures for rhinoviruses.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.